Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma

Lisa Licitra, S. Suardi, P. Bossi, L. D. Locati, L. Mariani, P. Quattrone, S. Lo Vullo, M. Oggionni, P. Olmi, G. Cantù, M. A. Pierotti, S. Pilotti

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Purpose: To assess the role of TP53 status in predicting pathologic complete remission after primary chemotherapy in patients with ethmoidal intestinal-type adenocarcinoma (ITAC). Patients and Methods: Thirty patients with ethmoidal ITAC enrolled onto a phase II study received chemotherapy with cisplatin, fluorouracil, and leucovorin (PFL) followed by surgery and radiation. On surgical specimens, absence of viable tumor cells was defined as pathologic complete remission (pCR). TP53 status/p53 function, analyzed on pretreatment biopsies, were retrospectively correlated with pathologic results and patient outcome. Results: Twelve patients achieved a pCR; 18 patients did not (overall response rate, 40%). In patients with wild-type (wt) TP53 or functional p53 protein, the pCRs were 83% and 80%, respectively; in patients with mutated TP53 or impaired p53 protein, pCRs were 11% and 0%, respectively (P ≤ .0001). At a median 55-month follow-up, all pCR patients were disease-free; 44% of nonresponding patients experienced relapse (P = .0061). Conclusion: The results indicate the existence of two genetic ITAC subgroups, defined by differences in TP53 mutational status or protein functionality, that strongly influence pathologic response to primary chemotherapy and, ultimately, prognosis. PFL seems to be highly effective in terms of pCR and disease-free survival in the presence of a wt or a still-efficient p53 protein, even when encoded by a mutated TP53 gene (eg, early-stop codon mutation), but ineffective in ITACs carrying a disabled p53 protein. Whether this model is extensible to other head and neck cancers needs appropriate investigation.

Original languageEnglish
Pages (from-to)4901-4906
Number of pages6
JournalJournal of Clinical Oncology
Volume22
Issue number24
DOIs
Publication statusPublished - Dec 15 2004

Fingerprint

Ethmoid Sinus
Leucovorin
Fluorouracil
Cisplatin
Adenocarcinoma
Drug Therapy
Proteins
Terminator Codon
p53 Genes
Head and Neck Neoplasms
Disease-Free Survival
Radiation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma. / Licitra, Lisa; Suardi, S.; Bossi, P.; Locati, L. D.; Mariani, L.; Quattrone, P.; Lo Vullo, S.; Oggionni, M.; Olmi, P.; Cantù, G.; Pierotti, M. A.; Pilotti, S.

In: Journal of Clinical Oncology, Vol. 22, No. 24, 15.12.2004, p. 4901-4906.

Research output: Contribution to journalArticle

@article{f169472346c8454c84d427dbc4a3bf47,
title = "Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma",
abstract = "Purpose: To assess the role of TP53 status in predicting pathologic complete remission after primary chemotherapy in patients with ethmoidal intestinal-type adenocarcinoma (ITAC). Patients and Methods: Thirty patients with ethmoidal ITAC enrolled onto a phase II study received chemotherapy with cisplatin, fluorouracil, and leucovorin (PFL) followed by surgery and radiation. On surgical specimens, absence of viable tumor cells was defined as pathologic complete remission (pCR). TP53 status/p53 function, analyzed on pretreatment biopsies, were retrospectively correlated with pathologic results and patient outcome. Results: Twelve patients achieved a pCR; 18 patients did not (overall response rate, 40{\%}). In patients with wild-type (wt) TP53 or functional p53 protein, the pCRs were 83{\%} and 80{\%}, respectively; in patients with mutated TP53 or impaired p53 protein, pCRs were 11{\%} and 0{\%}, respectively (P ≤ .0001). At a median 55-month follow-up, all pCR patients were disease-free; 44{\%} of nonresponding patients experienced relapse (P = .0061). Conclusion: The results indicate the existence of two genetic ITAC subgroups, defined by differences in TP53 mutational status or protein functionality, that strongly influence pathologic response to primary chemotherapy and, ultimately, prognosis. PFL seems to be highly effective in terms of pCR and disease-free survival in the presence of a wt or a still-efficient p53 protein, even when encoded by a mutated TP53 gene (eg, early-stop codon mutation), but ineffective in ITACs carrying a disabled p53 protein. Whether this model is extensible to other head and neck cancers needs appropriate investigation.",
author = "Lisa Licitra and S. Suardi and P. Bossi and Locati, {L. D.} and L. Mariani and P. Quattrone and {Lo Vullo}, S. and M. Oggionni and P. Olmi and G. Cant{\`u} and Pierotti, {M. A.} and S. Pilotti",
year = "2004",
month = "12",
day = "15",
doi = "10.1200/JCO.2004.05.071",
language = "English",
volume = "22",
pages = "4901--4906",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "24",

}

TY - JOUR

T1 - Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma

AU - Licitra, Lisa

AU - Suardi, S.

AU - Bossi, P.

AU - Locati, L. D.

AU - Mariani, L.

AU - Quattrone, P.

AU - Lo Vullo, S.

AU - Oggionni, M.

AU - Olmi, P.

AU - Cantù, G.

AU - Pierotti, M. A.

AU - Pilotti, S.

PY - 2004/12/15

Y1 - 2004/12/15

N2 - Purpose: To assess the role of TP53 status in predicting pathologic complete remission after primary chemotherapy in patients with ethmoidal intestinal-type adenocarcinoma (ITAC). Patients and Methods: Thirty patients with ethmoidal ITAC enrolled onto a phase II study received chemotherapy with cisplatin, fluorouracil, and leucovorin (PFL) followed by surgery and radiation. On surgical specimens, absence of viable tumor cells was defined as pathologic complete remission (pCR). TP53 status/p53 function, analyzed on pretreatment biopsies, were retrospectively correlated with pathologic results and patient outcome. Results: Twelve patients achieved a pCR; 18 patients did not (overall response rate, 40%). In patients with wild-type (wt) TP53 or functional p53 protein, the pCRs were 83% and 80%, respectively; in patients with mutated TP53 or impaired p53 protein, pCRs were 11% and 0%, respectively (P ≤ .0001). At a median 55-month follow-up, all pCR patients were disease-free; 44% of nonresponding patients experienced relapse (P = .0061). Conclusion: The results indicate the existence of two genetic ITAC subgroups, defined by differences in TP53 mutational status or protein functionality, that strongly influence pathologic response to primary chemotherapy and, ultimately, prognosis. PFL seems to be highly effective in terms of pCR and disease-free survival in the presence of a wt or a still-efficient p53 protein, even when encoded by a mutated TP53 gene (eg, early-stop codon mutation), but ineffective in ITACs carrying a disabled p53 protein. Whether this model is extensible to other head and neck cancers needs appropriate investigation.

AB - Purpose: To assess the role of TP53 status in predicting pathologic complete remission after primary chemotherapy in patients with ethmoidal intestinal-type adenocarcinoma (ITAC). Patients and Methods: Thirty patients with ethmoidal ITAC enrolled onto a phase II study received chemotherapy with cisplatin, fluorouracil, and leucovorin (PFL) followed by surgery and radiation. On surgical specimens, absence of viable tumor cells was defined as pathologic complete remission (pCR). TP53 status/p53 function, analyzed on pretreatment biopsies, were retrospectively correlated with pathologic results and patient outcome. Results: Twelve patients achieved a pCR; 18 patients did not (overall response rate, 40%). In patients with wild-type (wt) TP53 or functional p53 protein, the pCRs were 83% and 80%, respectively; in patients with mutated TP53 or impaired p53 protein, pCRs were 11% and 0%, respectively (P ≤ .0001). At a median 55-month follow-up, all pCR patients were disease-free; 44% of nonresponding patients experienced relapse (P = .0061). Conclusion: The results indicate the existence of two genetic ITAC subgroups, defined by differences in TP53 mutational status or protein functionality, that strongly influence pathologic response to primary chemotherapy and, ultimately, prognosis. PFL seems to be highly effective in terms of pCR and disease-free survival in the presence of a wt or a still-efficient p53 protein, even when encoded by a mutated TP53 gene (eg, early-stop codon mutation), but ineffective in ITACs carrying a disabled p53 protein. Whether this model is extensible to other head and neck cancers needs appropriate investigation.

UR - http://www.scopus.com/inward/record.url?scp=16644403520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16644403520&partnerID=8YFLogxK

U2 - 10.1200/JCO.2004.05.071

DO - 10.1200/JCO.2004.05.071

M3 - Article

VL - 22

SP - 4901

EP - 4906

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 24

ER -